JP2020536085A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536085A5
JP2020536085A5 JP2020518682A JP2020518682A JP2020536085A5 JP 2020536085 A5 JP2020536085 A5 JP 2020536085A5 JP 2020518682 A JP2020518682 A JP 2020518682A JP 2020518682 A JP2020518682 A JP 2020518682A JP 2020536085 A5 JP2020536085 A5 JP 2020536085A5
Authority
JP
Japan
Prior art keywords
treatment
combination according
tuberculosis
medicament
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020518682A
Other languages
English (en)
Other versions
JP2020536085A (ja
JP7233059B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/077222 external-priority patent/WO2019068910A1/en
Publication of JP2020536085A publication Critical patent/JP2020536085A/ja
Publication of JP2020536085A5 publication Critical patent/JP2020536085A5/ja
Application granted granted Critical
Publication of JP7233059B2 publication Critical patent/JP7233059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (2)

  1. 治療における医薬品として使用するための、請求項１〜１３のいずれか１項に記載の組み合わせ。
  2. 結核の治療及び／又は予防のための薬剤の製造のための、請求項１〜１４のいずれか１項に記載の組み合わせ。
JP2020518682A 2017-10-05 2018-10-05 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン Active JP7233059B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568430P 2017-10-05 2017-10-05
US62/568,430 2017-10-05
US201862716054P 2018-08-08 2018-08-08
US62/716,054 2018-08-08
PCT/EP2018/077222 WO2019068910A1 (en) 2017-10-05 2018-10-05 THIAZOLINO 2-PYRIDONES WITH A FUSED CYCLE IN COMBINATION WITH A MEDICINE AGAINST TUBERCULOSIS

Publications (3)

Publication Number Publication Date
JP2020536085A JP2020536085A (ja) 2020-12-10
JP2020536085A5 true JP2020536085A5 (ja) 2021-11-11
JP7233059B2 JP7233059B2 (ja) 2023-03-06

Family

ID=63840820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518682A Active JP7233059B2 (ja) 2017-10-05 2018-10-05 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン

Country Status (7)

Country Link
US (1) US11129816B2 (ja)
EP (1) EP3691619A1 (ja)
JP (1) JP7233059B2 (ja)
KR (1) KR20200066315A (ja)
CN (1) CN111246848A (ja)
PH (1) PH12020550567A1 (ja)
WO (1) WO2019068910A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003521B1 (en) * 2019-07-30 2024-05-29 Qurient Co. Ltd. Different forms of 6-chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
EP4146659A1 (en) * 2020-05-08 2023-03-15 Quretech Bio AB Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
CN112921107A (zh) * 2020-12-31 2021-06-08 深圳市慢性病防治中心(深圳市皮肤病防治研究所、深圳市肺部疾病防治研究所) 结核分枝杆菌异质性耐药检测方法、试剂盒及应用
CN113045494B (zh) * 2021-03-29 2022-04-26 四川大学华西医院 吡啶酮衍生物及其在制备预防和/或治疗结核分枝杆菌所引起的结核病的药物中的用途
CN115531388B (zh) * 2022-11-04 2024-03-22 首都医科大学附属北京胸科医院 治疗结核病的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101732212B1 (ko) 2010-03-18 2017-05-02 재단법인 한국파스퇴르연구소 항감염성 화합물
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
US10425481B2 (en) 2013-05-13 2019-09-24 Telefonaktiebolaget Lm Ericsson (Publ) Node in a telecommunications network, a virtual network element and methods for retrieving resource identification information
WO2014185853A1 (en) 2013-05-14 2014-11-20 Quretech Bio Ab Compounds and methods for treatment of chlamydia infections
MY174007A (en) * 2013-07-26 2020-03-03 Sanofi Sa Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
RU2734760C2 (ru) 2013-08-02 2020-10-23 Энститю Пастер Корея Противоинфекционные соединения
CA2966960C (en) 2014-11-13 2022-09-27 Quretech Bio Ab 2,3-dihydro-thiazolo[3,2-a]pyridin-5-one derivatives, intermediates thereof, and their use as antibacterial agents
ES2870230T3 (es) * 2016-04-08 2021-10-26 Quretech Bio Ab Tiazolin-2-piridonas de anillo condensado, métodos para la preparación de las mismas y su uso en el tratamiento y/o la prevención de la tuberculosis

Similar Documents

Publication Publication Date Title
JP2020536085A5 (ja)
JP2015057451A5 (ja)
JP2016523252A5 (ja)
EP4335418A3 (en) Compositions and methods for treating pterygium
JP2016515522A5 (ja)
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2018004283A3 (ko) 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
WO2015077503A8 (en) Autotaxin inhibitor compounds
JP2016147915A5 (ja)
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
SG11202112111WA (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
JP2018202656A5 (ja)
JP2017197541A5 (ja)
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
JP2016540019A5 (ja)
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
JP2019526545A5 (ja)
WO2015165980A3 (en) Treatment and prevention of alzheimer's disease (ad)
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán